Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.080 | AlteredExpression | disease | BEFREE | Two tumors with high phospho-ALK levels and low phospho-EGFR levels achieved stable and progressive disease, respectively. | 24443522 | 2014 | ||||
|
0.080 | Biomarker | disease | BEFREE | Although most patients with ALK-positive non-small-cell lung cancer (NSCLC) who benefit from treatment with crizotinib ultimately develop progressive disease (PD), continuing crizotinb beyond the initial PD (CBPD) in these patients may be beneficial. | 28427213 | 2017 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | One patient had an ALK G1202R mutation in a post-alectinib/pre-brigatinib biopsy, and had progressive disease as the best overall response to brigatinib. | 29935304 | 2018 | ||||
|
0.080 | Biomarker | disease | BEFREE | In advanced ALK positive NSCLC PET was able to detect progressive disease earlier than with CT in nearly half of the assessments while both imaging tests performed similar in the others. | 27137772 | 2016 | ||||
|
0.080 | Biomarker | disease | BEFREE | <b>Objectives:</b> To study whether ongoing clinical benefits of continuing anaplastic lymphoma kinase <i>(ALK)</i> and c-ros oncogene 1 (<i>ROS1</i>) inhibition are achieved by crizotinib treatment post progressive disease (PD) in advanced non-small cell lung cancer (NSCLC) patients harboring <i>ALK</i>/<i>ROS1</i> mutations. | 29805713 | 2018 | ||||
|
0.080 | Biomarker | disease | BEFREE | Four ALK positive patients with progressive disease following crizotinib treatment were identified with paired pre- and post-crizotinib tumor tissue from our previously published cohort. | 29300322 | 2018 | ||||
|
0.080 | Biomarker | disease | BEFREE | All but one patient had no ground-glass opacity (GGO) lesions, indicating that most ALK-positive tumors showed a solid growth pattern without GGO on CT. Twenty were evaluable for response to chemotherapy; 10 (50.0%) had a partial response (PR), nine (45.0%) had stable disease (SD), and one (5.0%) had progressive disease (PD) with first-line chemotherapy. | 24403104 | 2014 | ||||
|
0.080 | Biomarker | disease | BEFREE | The appropriate therapy for patients with progressive disease following two ALK inhibitors is not well defined. | 28534251 | 2017 |